Cargando…

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how

Dual antiplatelet therapy (DAPT) for 6–12 months, followed by lifelong aspirin monotherapy is considered an effective standard therapy for the prevention of thrombo-ischemic events in patients with acute and chronic coronary syndrome (ACS, CCS) undergoing percutaneous coronary intervention (PCI) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muthspiel, Marie, Kaufmann, Christoph C., Burger, Achim Leo, Panzer, Benjamin, Verheugt, Freek W. A., Huber, Kurt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684463/ https://www.ncbi.nlm.nih.gov/pubmed/36440022 http://dx.doi.org/10.3389/fcvm.2022.1008194

Ejemplares similares

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
por: Lee, Sang Yeub, et al.
Publicado: (2023)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
por: Mourikis, Philipp, et al.
Publicado: (2023)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
por: Galli, Mattia, et al.
Publicado: (2022)

Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation
por: Lüsebrink, Enzo, et al.
Publicado: (2019)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
por: Cui, Kongyong, et al.
Publicado: (2021)

Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients
por: Sun, Chengming, et al.
Publicado: (2022)

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy
por: Wadowski, Patricia P., et al.
Publicado: (2017)

Erratum: Correction of Text in the Article “Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI”
por: Ki, You-Jeong, et al.
Publicado: (2022)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Zhao, Zhigang, et al.
Publicado: (2023)

Erratum to: Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

The Role of Antiplatelet Therapy in Patients With MINOCA
por: Ortega-Paz, Luis, et al.
Publicado: (2022)

Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy
por: Hong, Bum-Kee
Publicado: (2010)

Dental extraction in patients receiving dual antiplatelet therapy
por: Sánchez-Palomino, Paulino, et al.
Publicado: (2015)

Surgical tracheotomy performed with and without dual antiplatelet therapy
por: Markota, Andrej, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

The use of dual antiplatelet therapy for ischemic cerebrovascular events
por: Mele, Francesco, et al.
Publicado: (2022)

Dual Antiplatelet Therapy: A Concise Review for Clinicians
por: Virk, Hafeez Ul Hassan, et al.
Publicado: (2023)

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy
por: Gremmel, Thomas, et al.
Publicado: (2015)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation
por: Staudacher, Dawid L., et al.
Publicado: (2016)

Comparison of the Degree of Gastric Mucosal Injury between Patients Who Are Receiving Dual Antiplatelet Therapy or Single Antiplatelet Therapy
por: Shimada, Yuji, et al.
Publicado: (2022)

Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
por: Magnani, Giulia, et al.
Publicado: (2023)

Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction
por: Roh, Ji Woong, et al.
Publicado: (2021)

Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy
por: de Breet, C. P. D. M., et al.
Publicado: (2021)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy
por: Patail, Haris, et al.
Publicado: (2023)

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction
por: Weiss, Thomas W., et al.
Publicado: (2016)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_recselts08sj8cen7dmehoqsug